Table S2. Univariate competing risk analyses of clinical-pathological factors and IHC markers associated with site-specific recurrence.
| Variable | Thoracic recurrence | Brain recurrence | Bone recurrence | Abdominal recurrence | Neck recurrence | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||||
| Age (≤65 vs. >65) | 1.22 (0.83–1.80) | 0.307 | 0.59 (0.25–1.40) | 0.233 | 1.10 (0.54–2.25) | 0.788 | 0.94 (0.26–3.36) | 0.918 | 1.02 (0.28–3.70) | 0.982 | ||||
| Sex (F vs. M) | 1.52 (1.08–2.14) | 0.018 | 0.71 (0.36–1.40) | 0.324 | 0.69 (0.35–1.25) | 0.279 | 1.68 (0.59–4.80) | 0.330 | 1.04 (0.34–3.18) | 0.946 | ||||
| Smoking (N vs. E) | 1.32 (1.12–1.57) | 0.042 | 0.89 (0.67–0.97) | 0.036 | 0.97 (0.74–1.76) | 0.872 | 1.78 (0.67–2.38) | 0.721 | 1.83 (0.85–4.32) | 0.107 | ||||
| Tumor size (≤2.0 vs. >2.0) | 2.18 (1.53–3.10) | <0.001 | 6.21 (2.75–14.0) | <0.001 | 2.66 (1.38–5.15) | 0.004 | 7.35 (1.64–32.9) | 0.009 | 6.53 (1.44–25.5) | 0.015 | ||||
| N (N0–1 vs. N2) | 3.05 (2.06–4.51) | <0.001 | 4.10 (2.13–7.89) | <0.001 | 4.08 (2.14–7.78) | <0.001 | 9.36 (3.20–27.4) | <0.001 | 15.2 (4.60–50.4) | <0.001 | ||||
| Histology (G vs. A) | 1.85 (1.16–2.95) | 0.010 | 2.63 (1.25–5.50) | 0.011 | 1.29 (0.51–3.29) | 0.595 | 1.57 (0.35–7.03) | 0.555 | 3.95 (1.22–12.8) | 0.022 | ||||
| Differentiation (W vs. P) | 1.42 (0.78–2.56) | 0.253 | 2.51 (0.98–6.40) | 0.054 | 2.38 (0.93–6.61) | 0.070 | 6.58 (2.06–21.0) | 0.001 | 5.15 (1.42–18.7) | 0.013 | ||||
| LVI (− vs. +) | 2.06 (1.38–3.07) | <0.001 | 2.67 (1.36–5.27) | 0.005 | 2.23 (1.11–4.49) | 0.024 | 2.40 (0.74–7.75) | 0.143 | 4.94 (1.63–14.9) | 0.005 | ||||
| VPI (− vs. +) | 1.99 (1.37–2.89) | <0.001 | 2.02 (1.03–4.00) | 0.040 | 2.85 (1.51–5.38) | 0.001 | 1.97 (0.62–6.28) | 0.253 | 1.48 (0.41–5.39) | 0.550 | ||||
| ECOG (0–1 vs. 2) | 2.21 (0.78–3.21) | 0.764 | 3.17 (0.87–5.21) | 0.427 | 3.87 (0.67–7.83) | 0.163 | 3.71 (0.65–5.82) | 0.214 | 3.18 (0.81–5.21) | 0.308 | ||||
| EGFR mutation (C vs. U) | 0.91 (0.56–1.49) | 0.712 | 0.72 (0.26–2.03) | 0.538 | 0.54 (0.17–1.74) | 0.298 | 0.52 (0.07–4.00) | 0.529 | 0.59 (0.08–4.58) | 0.617 | ||||
| HER2 (− vs. +) | 1.10 (0.75–1.61) | 0.633 | 1.75 (0.83–3.70) | 0.146 | 1.71 (0.85–3.44) | 0.134 | 0.38 (0.08–1.78) | 0.214 | 1.39 (0.40–4.81) | 0.601 | ||||
| Ki67 (≤10% vs. >10%) | 2.25 (1.55–3.28) | <0.001 | 4.24 (1.92–9.38) | <0.001 | 3.14 (1.51–6.55) | 0.002 | 5.27 (1.12–24.9) | 0.036 | 2.09 (0.61–7.16) | 0.239 | ||||
| TTF1 (− vs. +) | 0.56 (0.32–0.96) | 0.034 | 0.86 (0.35–2.11) | 0.743 | 0.57 (0.20–1.62) | 0.289 | 0.75 (0.15–3.62) | 0.716 | 0.03 (0.00–24.9) | 0.310 | ||||
| CK20 (− vs. +) | 1.98 (1.09–3.62) | 0.026 | 4.03 (1.64–9.93) | 0.002 | 2.26 (0.79–4.68) | 0.128 | 2.14 (0.26–17.5) | 0.476 | 0.05 (0.00–218) | 0.573 | ||||
| CK7 (− vs. +) | 0.55 (0.33–0.94) | 0.028 | 0.39 (0.12–1.29) | 0.121 | 0.74 (0.28–1.98) | 0.547 | 0.67 (0.13–3.52) | 0.638 | 0.03 (0.00–18.8) | 0.277 | ||||
| CK5/6 (− vs. +) | 2.76 (1.43–5.31) | 0.003 | 0.95 (0.13–7.00) | 0.957 | 1.71 (0.41–7.26) | 0.464 | 6.30 (1.30–30.5) | 0.022 | 0.05 (0.00–945) | 0.687 | ||||
| P63 (− vs. +) | 1.09 (0.71–1.66) | 0.704 | 0.58 (0.22–1.53) | 0.272 | 1.63 (0.77–3.47) | 0.204 | 0.88 (0.23–3.40) | 0.860 | 2.12 (0.56–8.00) | 0.267 | ||||
| RRM1 (− vs. +) | 0.86 (0.52–1.43) | 0.570 | 1.56 (0.47–5.12) | 0.465 | 0.87 (0.33–2.24) | 0.766 | 0.61 (0.13–2.93) | 0.533 | 1.48 (0.19–11.6) | 0.706 | ||||
| NapsinA (− vs. +) | 1.04 (0.59–1.84) | 0.895 | 1.34 (0.40–4.46) | 0.632 | 1.32 (0.40–4.39) | 0.646 | 1.64 (0.21–12.9) | 0.638 | 1.06 (0.13–8.83) | 0.954 | ||||
| Syn (− vs. +) | 0.91 (0.36–2.31) | 0.840 | 4.29 (1.40–13.1) | 0.011 | 0.48 (0.06–3.61) | 0.472 | 0.04 (0.00–524) | 0.656 | 0.04 (0.00–985) | 0.536 | ||||
IHC, immunohistochemical; EGFR, epidermal growth factor receptor; HR, hazard ratios; CI, confidence intervals; LVI, lymphovascular invasion; VPI, visceral pleural invasion; ECOG, the Eastern Corporative Oncology Group. F, female; M, male; N, Never; E, Ever; G, general; A, aggressive; W, well/moderate; P, poor; C, common mutations; U, uncommon mutations.